Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis.

Caputo R, Buono G, Martinelli C, Botticelli A, Caltavituro A, Pantano F, Guarino A, Bonomo MV, Diana A, Carlino F, Rizzo A, Giotta F, Orlando L, Sanò MV, Staropoli N, Von Arx C, Pernice G, Stucci S, Bajardi EA, Ricciardi GR, Turano S, Poggio FB, Cinieri S, Orditura M, Arpino G, Giuliano M, Fabi A, Piezzo M, Del Mastro L, De Laurentiis M

Open source

DOI: 10.1016/j.esmoop.2026.108251
Published: 2026 Jul
Container: ESMO open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2026.108251,
  title = {Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis.},
  author = {Caputo R and Buono G and Martinelli C and Botticelli A and Caltavituro A and Pantano F and Guarino A and Bonomo MV and Diana A and Carlino F and Rizzo A and Giotta F and Orlando L and Sanò MV and Staropoli N and Von Arx C and Pernice G and Stucci S and Bajardi EA and Ricciardi GR and Turano S and Poggio FB and Cinieri S and Orditura M and Arpino G and Giuliano M and Fabi A and Piezzo M and Del Mastro L and De Laurentiis M},
  year = {2026},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2026.108251},
  url = {https://doi.org/10.1016/j.esmoop.2026.108251}
}

RIS

TY  - JOUR
TI  - Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis.
AU  - Caputo R
AU  - Buono G
AU  - Martinelli C
AU  - Botticelli A
AU  - Caltavituro A
AU  - Pantano F
AU  - Guarino A
AU  - Bonomo MV
AU  - Diana A
AU  - Carlino F
AU  - Rizzo A
AU  - Giotta F
AU  - Orlando L
AU  - Sanò MV
AU  - Staropoli N
AU  - Von Arx C
AU  - Pernice G
AU  - Stucci S
AU  - Bajardi EA
AU  - Ricciardi GR
AU  - Turano S
AU  - Poggio FB
AU  - Cinieri S
AU  - Orditura M
AU  - Arpino G
AU  - Giuliano M
AU  - Fabi A
AU  - Piezzo M
AU  - Del Mastro L
AU  - De Laurentiis M
PY  - 2026
JO  - ESMO open
DO  - 10.1016/j.esmoop.2026.108251
UR  - https://doi.org/10.1016/j.esmoop.2026.108251
ER  -

APA

R, C., G, B., C, M., A, B., A, C., F, P., A, G., MV, B., A, D., F, C., A, R., F, G., L, O., MV, S., N, S., C, V. A., G, P., S, S., EA, B., GR, R., S, T., FB, P., S, C., M, O., G, A., M, G., A, F., M, P., L, D. M., & M, D. L. (2026). Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis.. ESMO open. https://doi.org/10.1016/j.esmoop.2026.108251

Source records

pubmed · retrieved 2026-09-26T06:25:28.340Z